Data completeness
3/8 — Basic
BETAMETHASONE VALERATE (betamethasone valerate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. Approved for psoriasis, atopic eczema, hand eczema.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Betamethasone Valerate is a topical corticosteroid ointment that reduces inflammation, itching, and redness through unclear anti-inflammatory mechanisms and vasoconstriction. It is indicated for psoriasis, atopic eczema, and hand eczema, with absorption and systemic handling dependent on skin barrier integrity and occlusive dressing use. The product is currently in pre-launch stage under Sandoz sponsorship.
$0.074BPart D
GrowthPre-launch stage with modest current utilization (247 Part D claims in 2023) signals early-stage commercial build requiring field sales expansion and market access teams.
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications (3)
Investigational (3)
Worked on BETAMETHASONE VALERATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.